Interventional technology developer Boston Scientific said that U.S. District Court for the District of New Jersey has ruled in its favor in a patent infringement suit filed by Johnson & Johnson.
The ruling found all asserted patents to be invalid and entered judgment in favor of Boston Scientific, according to the company. Johnson & Johnson had alleged in a 2008 suit that Boston Scientific's Promus everolimus-eluting coronary stent system infringed two patents (U.S. Patent No. 5,516,781 and No. 5,563,146) relating to the use of a drug on a drug-eluting stent.
